Incyte Corp gains 16% in a week, boosted by strong Q1 2026 results and new product expansion.

Incyte Corporation's stock rose about 16% in one week, outperforming the broader market amid a sell-off. The company reported strong Q1 2026 results with 21% revenue growth, 56% adjusted EPS increase, and a 63% rise in sales excluding its main drug Jakafi. Recent positive developments include a favorable CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, which diversifies its product portfolio and reduces reliance on Jakafi. While risks remain in execution beyond Jakafi and potential M&A challenges, Incyte's valuation looks attractive if its pipeline delivers and analysts raise earnings forecasts.